Behavioural brain research
February 1, 2019
Arvie Abiero, Chrislean Jun Botanas, Leandro Val Sayson et al.
17 citations
5-MeO-AMT, a tryptamine used recreationally for its hallucinogenic and mood-elevating effects, triggers head-twitch response (HTR) in mice through activation of serotonin receptor 2a (5-HTR2a) in the prefrontal cortex. Acute administration at doses 0.3–10 mg/kg produced HTR, but repeated dosing led to tolerance. The 5-HTR2a antagonist ketanserin blocked the response. The drug increased 5-HTR2a mRNA and induced PKC-γ phosphorylation in the prefrontal cortex. 5-MeO-AMT did not produce locomotor sensitization, conditioned place preference, or self-administration, suggesting low abuse potential.
International journal of molecular sciences
June 29, 2020
In Soo Ryu, Oc-Hee Kim, Young Eun Lee et al.
The designer drug 4'-F-PCP, a derivative of the dissociative anesthetic phencyclidine (PCP), shows a high potential for abuse. In rodents, a 10 mg/kg dose increased movement and rearing, and produced conditioned place preference, indicating rewarding effects. Intravenous self-administration of 1.0 mg/kg/infusion was robust, with a higher breakpoint under progressive ratio schedules, suggesting strong reinforcing properties. The drug altered dopamine transporter and D1 receptor expression in the nucleus accumbens and increased phosphorylated ERK, CREB, c-Fos, and FosB/ΔFosB, indicating activation of dopamine-related signaling pathways. These findings indicate that 4'-F-PCP has significant abuse liability.
Psychopharmacology
March 1, 2020
Arvie Abiero, Chrislean Jun Botanas, Raly James Custodio et al.
Two synthetic dissociative drugs, 4-MeO-PCP and 3-MeO-PCMo, produce rewarding and reinforcing effects in rats, indicating potential for abuse in humans. Both drugs induced conditioned place preference and self-administration, but only 4-MeO-PCP caused locomotor sensitization. Blocking dopamine D1 or D2 receptors prevented the drugs' rewarding effects. The drugs altered dopamine-related proteins and increased delta and gamma brain wave activity, effects also blocked by dopamine antagonists. These findings suggest the drugs' abuse potential is mediated through the mesolimbic dopamine system.